NBP 14
Alternative Names: NBP-14Latest Information Update: 28 Apr 2024
At a glance
- Originator Neuro-Bio
- Class Antidementias; Peptides
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in United Kingdom (Intranasal, Spray)
- 14 Apr 2022 NBP 14 is available for licensing as of 14 Apr 2022. https://neuro-bio.com/investors-and-partnering/
- 14 Apr 2022 Neuro-Bio announces intention to file IND application for NBP 14 in Alzheimer's disease (Neuro-Bio website, April 2022)